CN103842372A - 环孢菌素衍生物 - Google Patents
环孢菌素衍生物 Download PDFInfo
- Publication number
- CN103842372A CN103842372A CN201280042682.1A CN201280042682A CN103842372A CN 103842372 A CN103842372 A CN 103842372A CN 201280042682 A CN201280042682 A CN 201280042682A CN 103842372 A CN103842372 A CN 103842372A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- group
- alkyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(*)(*(*)C(*)C(CCC1)(I)I*)C(*2)=C1N=C2SC Chemical compound CC(*)(*(*)C(*)C(CCC1)(I)I*)C(*2)=C1N=C2SC 0.000 description 5
- XKKOSMWEPZCCAC-UHFFFAOYSA-N CCC(NC(CCC(O)=O)C(NC(CCC(O)=O)C(O)=O)=O)=O Chemical compound CCC(NC(CCC(O)=O)C(NC(CCC(O)=O)C(O)=O)=O)=O XKKOSMWEPZCCAC-UHFFFAOYSA-N 0.000 description 1
- RDHDFVPVFTZSMQ-MUORALELSA-N CC[C@@H](C(N(C)CC(N(C)/C(/C(N[C@@H](C(C)C)C(N(C)[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)C(CC(C)C)C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1[C@@H]([C@H](C)Cc2nc3cc(C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N)=O)=O)=O)ccc3[nH]2)O)=O)=O)=O)=O)=O)=O)=O)=O)=C\C(C)C)=O)=O)NC1=O Chemical compound CC[C@@H](C(N(C)CC(N(C)/C(/C(N[C@@H](C(C)C)C(N(C)[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)C(CC(C)C)C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1[C@@H]([C@H](C)Cc2nc3cc(C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N)=O)=O)=O)ccc3[nH]2)O)=O)=O)=O)=O)=O)=O)=O)=O)=C\C(C)C)=O)=O)NC1=O RDHDFVPVFTZSMQ-MUORALELSA-N 0.000 description 1
- DUKZBMIQBRXSFO-MUSBHIQNSA-N CC[C@@H](C(N(C)CC(N(C)[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N(C)[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1[C@@H]([C@H](C)Cc2nc(/C=C\C)c(C)[nH]2)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O Chemical compound CC[C@@H](C(N(C)CC(N(C)[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N(C)[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1[C@@H]([C@H](C)Cc2nc(/C=C\C)c(C)[nH]2)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O DUKZBMIQBRXSFO-MUSBHIQNSA-N 0.000 description 1
- VTBUHUZTKRVXKJ-QGQVREQKSA-N CC[C@@H](C(N(C)CC(N(C)[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N(C)[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1[C@@H]([C@H](C)Cc2nc(cc(cc3)C(N[C@@H](CCC(OCc4ccccc4)=O)C(N[C@@H](CCC(OCc4ccccc4)=O)C(N)=O)=O)=O)c3[nH]2)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O Chemical compound CC[C@@H](C(N(C)CC(N(C)[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N(C)[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1[C@@H]([C@H](C)Cc2nc(cc(cc3)C(N[C@@H](CCC(OCc4ccccc4)=O)C(N[C@@H](CCC(OCc4ccccc4)=O)C(N)=O)=O)=O)c3[nH]2)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O VTBUHUZTKRVXKJ-QGQVREQKSA-N 0.000 description 1
- AHRIDDXDBNPYIZ-SFIJKNBRSA-N CC[C@@H](C(N(C)CC(N(C)[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N(C)[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1[C@@H]([C@H](C)Cc2nc3cc(-c4nnn[nH]4)ccc3[nH]2)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O Chemical compound CC[C@@H](C(N(C)CC(N(C)[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N(C)[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1[C@@H]([C@H](C)Cc2nc3cc(-c4nnn[nH]4)ccc3[nH]2)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O AHRIDDXDBNPYIZ-SFIJKNBRSA-N 0.000 description 1
- PHWZJCGTPQVGBA-DEYFJTMHSA-N CC[C@@H](C(N(C)CC(N(C)[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N(C)[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CCC(C)C)C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1[C@@H]([C@H](C)Cc2nc3cc(C(NCCN(CC4)CCN4C(CCC(O)=O)=O)=O)ccc3[nH]2)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O Chemical compound CC[C@@H](C(N(C)CC(N(C)[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N(C)[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CCC(C)C)C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1[C@@H]([C@H](C)Cc2nc3cc(C(NCCN(CC4)CCN4C(CCC(O)=O)=O)=O)ccc3[nH]2)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O PHWZJCGTPQVGBA-DEYFJTMHSA-N 0.000 description 1
- XZGLNCKSNVGDNX-UHFFFAOYSA-N Cc1nnn[nH]1 Chemical compound Cc1nnn[nH]1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y502/00—Cis-trans-isomerases (5.2)
- C12Y502/01—Cis-trans-Isomerases (5.2.1)
- C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011111991A DE102011111991A1 (de) | 2011-08-30 | 2011-08-30 | Neue Cyclosporin-Derivate |
| DE102011111991.8 | 2011-08-30 | ||
| PCT/EP2012/066726 WO2013030208A1 (de) | 2011-08-30 | 2012-08-29 | Cyclosporin-derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103842372A true CN103842372A (zh) | 2014-06-04 |
Family
ID=46754993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280042682.1A Pending CN103842372A (zh) | 2011-08-30 | 2012-08-29 | 环孢菌素衍生物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9453051B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2751127B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6240072B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103842372A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012300934B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2845663C (cg-RX-API-DMAC7.html) |
| DE (1) | DE102011111991A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2601029T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013030208A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0737730Y2 (ja) | 1989-10-04 | 1995-08-30 | 横河電機株式会社 | 溶射装置 |
| US9428845B1 (en) | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| CN104513296B (zh) * | 2013-09-27 | 2018-03-02 | 王喆明 | 一种环肽化合物及其用途 |
| WO2016112295A1 (en) | 2015-01-09 | 2016-07-14 | Warp Drive Bio, Inc. | Compounds that participate in cooperative binding and uses thereof |
| CA3000822A1 (en) * | 2015-10-01 | 2017-04-06 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| CA3020594A1 (en) | 2016-04-12 | 2017-10-19 | Warp Drive Bio, Inc. | Compositions and methods for the production of compounds |
| US12594275B2 (en) | 2019-02-07 | 2026-04-07 | The Regents Of The University Of California | Immunophilin binding agents and uses thereof |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| CN121471132A (zh) | 2019-11-04 | 2026-02-06 | 锐新医药公司 | Ras抑制剂 |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2021173474A1 (en) * | 2020-02-26 | 2021-09-02 | Bacainn Biotherapeutics, Ltd. | Cyclosporine compositions and methods of use |
| CA3172535A1 (en) * | 2020-03-26 | 2021-09-30 | Ching-Pong Mak | Cyclophilin inhibitors and uses thereof |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| WO2022192716A1 (en) * | 2021-03-11 | 2022-09-15 | Massachusetts Institute Of Technology | Small molecule suppressors of apoe gene expression and cerebral vascular amyloid pathology |
| CN112919984B (zh) * | 2021-04-16 | 2022-03-08 | 安徽硒无忧现代农业科技有限公司 | 一种生态化富硒有机营养液及其制备方法 |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2205317A (en) * | 1987-06-03 | 1988-12-07 | Merck & Co Inc | New cyclosporin analogs with modified }c-9-amino acids} |
| US20060069016A1 (en) * | 2004-09-29 | 2006-03-30 | Amr Technology, Inc. | Cyclosporin alkyne analogues and their pharmaceutical uses |
| US20100009390A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Mutant antibodies with high affinity for egfr |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1506200A (en) * | 1975-04-30 | 1978-04-05 | Farmaceutici Italia | Glycosides |
| US4672044A (en) | 1984-08-24 | 1987-06-09 | Scripps Clinic & Research Foundation | Murine monoclonal antibody combining site to human C3b receptor (CR1) |
| GB8426672D0 (en) * | 1984-10-22 | 1984-11-28 | Erba Farmitalia | Pharmaceutical compositions |
| AT401823B (de) | 1993-09-30 | 1996-12-27 | Avl Verbrennungskraft Messtech | Optischer indikator zur bestimmung der aktivität eines ions in einer probe |
| AUPO395396A0 (en) | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| PT848009E (pt) * | 1996-12-16 | 2000-11-30 | Pharmachemie Bv | Processo para a preparacao de epirubicina ou seus sais de adicao de acido a partir de daunorubicina |
| CA2285454A1 (en) | 1997-04-07 | 1998-10-15 | Axys Pharmaceuticals Corporation | Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity |
| FR2762843B1 (fr) * | 1997-04-30 | 1999-12-10 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| DE69832984T2 (de) | 1997-10-08 | 2006-09-21 | Isotechnika, Inc., Edmonton | DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN |
| US6221914B1 (en) | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
| WO2000020400A1 (en) | 1998-10-05 | 2000-04-13 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions for treating hepatitis c infections |
| DE19859910C2 (de) | 1998-12-23 | 2001-03-22 | Ratiopharm Gmbh | Orales Arzneimittel |
| IL135884A (en) | 2000-04-30 | 2005-08-31 | Yissum Res Dev Co | Method for measuring non-transferrin bound iron |
| US6596499B2 (en) | 2000-11-30 | 2003-07-22 | The Netherlands Cancer Institute | Membrane molecule indicator compositions and methods |
| US6784156B2 (en) * | 2001-03-05 | 2004-08-31 | Enanta Pharmaceuticals, Inc. | Cyclosporins for the treatment of respiratory diseases |
| WO2003087089A1 (en) | 2002-04-16 | 2003-10-23 | Teijin Limited | Piperidine derivatives having ccr3 antagonism |
| AU2003285958A1 (en) | 2002-10-25 | 2004-05-25 | Genesoft Pharmaceuticals, Inc. | Anti-infective biaryl compounds |
| WO2005004805A2 (en) * | 2003-07-02 | 2005-01-20 | Solux Corporation | Thermally stable crystalline epirubicin hydrochloride and method of making the same |
| US20090099346A1 (en) * | 2003-07-02 | 2009-04-16 | Victor Matvienko | Thermally stable crystalline epirubicin hydrochloride |
| DE10339597A1 (de) | 2003-08-26 | 2005-03-31 | Bayer Technology Services Gmbh | Vorrichtung und Verfahren zum Nachweis biochemischer Aktivität enthaltend Gap Junctions |
| AU2004276337B2 (en) | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| DE102006038403A1 (de) | 2006-08-17 | 2008-02-21 | Heinrich-Heine-Universität Düsseldorf | Verwendung bestimmter chemischer Verbindungen zur Inhibierung der Peptidyl-Prolyl-cis/trans-Isomeraseaktivität von Cyclophilinen |
| SG144809A1 (en) | 2007-01-11 | 2008-08-28 | Millipore U K Ltd | Benzimidazole compounds and their use as chromatographic ligands |
| PL1990405T3 (pl) * | 2007-05-08 | 2018-01-31 | Provivo Oy | Genetycznie zmodyfikowane szczepy wytwarzające metabolity będące antracyklinami użyteczne jako leki przeciwnowotworowe |
| MX2011001152A (es) | 2008-07-30 | 2011-06-09 | Isotechnika Pharma Inc | Moleculas de analogo de ciclosporina no-inmunesupresoras. |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| US8481483B2 (en) * | 2009-02-19 | 2013-07-09 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| DE102009037551A1 (de) | 2009-08-17 | 2011-02-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Cyclosporinderivate |
-
2011
- 2011-08-30 DE DE102011111991A patent/DE102011111991A1/de not_active Ceased
-
2012
- 2012-08-29 WO PCT/EP2012/066726 patent/WO2013030208A1/de not_active Ceased
- 2012-08-29 US US14/241,126 patent/US9453051B2/en active Active
- 2012-08-29 CA CA2845663A patent/CA2845663C/en active Active
- 2012-08-29 AU AU2012300934A patent/AU2012300934B2/en not_active Ceased
- 2012-08-29 EP EP12751509.6A patent/EP2751127B1/de active Active
- 2012-08-29 ES ES12751509.6T patent/ES2601029T3/es active Active
- 2012-08-29 JP JP2014527635A patent/JP6240072B2/ja not_active Expired - Fee Related
- 2012-08-29 CN CN201280042682.1A patent/CN103842372A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2205317A (en) * | 1987-06-03 | 1988-12-07 | Merck & Co Inc | New cyclosporin analogs with modified }c-9-amino acids} |
| US20060069016A1 (en) * | 2004-09-29 | 2006-03-30 | Amr Technology, Inc. | Cyclosporin alkyne analogues and their pharmaceutical uses |
| US20100009390A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Mutant antibodies with high affinity for egfr |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2601029T3 (es) | 2017-02-14 |
| WO2013030208A1 (de) | 2013-03-07 |
| EP2751127B1 (de) | 2016-07-27 |
| CA2845663A1 (en) | 2013-03-07 |
| AU2012300934B2 (en) | 2016-06-09 |
| AU2012300934A1 (en) | 2014-03-13 |
| EP2751127A1 (de) | 2014-07-09 |
| US9453051B2 (en) | 2016-09-27 |
| CA2845663C (en) | 2020-09-08 |
| DE102011111991A1 (de) | 2013-02-28 |
| JP6240072B2 (ja) | 2017-11-29 |
| JP2014531417A (ja) | 2014-11-27 |
| US20140316104A1 (en) | 2014-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2845663C (en) | Cyclosporin derivatives | |
| TWI882061B (zh) | 介白素-23受體之肽抑制劑及其治療發炎性疾病之用途 | |
| KR20240034223A (ko) | 인터류킨-23 수용체의 바이사이클릭 펩티드 억제제 | |
| US12421276B2 (en) | Methods of treating neurodegenerative disease with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues | |
| KR100579748B1 (ko) | 돌라스타틴 15 유도체 | |
| JP2007501866A (ja) | 胃腸疾患の治療のための方法および組成物 | |
| CN110240629A (zh) | 蛋白降解靶向bcr-abl化合物及其抗肿瘤应用 | |
| CN102159589A (zh) | 神经肽-2受体(y-2r)激动剂及其用途 | |
| CN116209671A (zh) | 补体因子c3的抑制剂及其医学用途 | |
| WO2012142142A2 (en) | Adiponectin receptor agonists and methods of use | |
| US9561290B2 (en) | Functionalized thieno-indole derivatives for the treatment of cancer | |
| KR20260038313A (ko) | 글리피칸-3을 표적화하는 펩티드 조성물 및 그의 용도 | |
| CN114890990B (zh) | 一种化合物及在制备nampt蛋白自噬降解剂中的应用 | |
| US11866518B2 (en) | Bicyclic peptide ligands specific for TSLP | |
| HK1195916A (en) | Cyclosporin derivatives | |
| WO2019181901A1 (ja) | 細胞移植を効率化する化合物 | |
| TW202426031A (zh) | EphA2結合待定肽及包含其之組成物 | |
| CN101578287B (zh) | 地索拉唑及其衍生物与细胞结合分子的轭合物,新的地索拉唑衍生物,其制备方法及其应用 | |
| CN120435304A (zh) | Ccr2抑制剂及使用方法 | |
| US10385096B2 (en) | Pro-Amb reverse turn restricted bioactive peptide analogues | |
| CN118852453A (zh) | 肠促胰素类似物及其制备方法和应用 | |
| HK40056369B (en) | Pyrimidine compound or salt thereof | |
| KR20250135269A (ko) | 인터루킨-23 수용체의 펩티드 억제제 | |
| BR122024027151A2 (pt) | Peptídeos monocíclicos e seus usos | |
| BR122024027142A2 (pt) | Inibidor peptídico do receptor de interleucina-23, composição farmacêutica, e uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1195916 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140604 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1195916 Country of ref document: HK |